Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance.
Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance. Net sales were up 15% on a constant currency basis to $13.2 billion
Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs.
Novartis on Tuesday issued a more optimistic full-year earnings guidance, citing strong growth of drugs such as Kisqali, Kesimpta and Leqvio during the first quarter.
Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manuf
President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, altho
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with repo
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE